By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the New Drug Application (NDA) for its self‑developed Class 1 innovative drug, ribupatide injection (HRS9531 injection), a dual GLP‑1/GIP receptor agonist, has been accepted by the National Medical Products Administration (NMPA) for the intended indication of glycemic control in adult patients with type 2 diabetes. Acceptance of the NDA moves Hengrui one regulatory step closer to potentially launching China’s homegrown dual‑agonist incretin therapy in the world’s largest diabetes market.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Filing Status | New Drug Application (NDA) accepted – formal review underway |
| Product | Ribupatide injection (HRS9531 injection); KAI‑9531 outside Greater China |
| Drug Class | Class 1 innovative drug – dual GLP‑1/GIP receptor agonist |
| Intended Indication | Glycemic control in adult patients with type 2 diabetes |
| Announcement Date | 9 September 2026 |
| Next Steps | NMPA technical review; approval timeline not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Ribupatide (HRS9531; known as KAI‑9531 outside Greater China), a proprietary dual glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP) receptor agonist developed in‑house by Hengrui.
- Mechanism: Co‑activation of the GLP‑1 and GIP incretin receptors is designed to produce complementary glucose‑dependent insulin secretion, glucagon suppression, and appetite regulation — the dual‑agonist approach clinically validated in cardiometabolic medicine.
- Formulations: Being developed in two dosage forms — a once‑weekly subcutaneous injection and a once‑daily oral tablet — offering both clinic‑administered and self‑managed routes.
- Origin: Self‑developed Class 1 innovative drug, retaining full intellectual property within Hengrui for the Greater China market.
Development Pipeline – Multi‑Indication Clinical Program in China
Clinical studies conducted in China for ribupatide injection span a broad cardiometabolic indication set:
- Weight management in adults and adolescents
- Type 2 diabetes (the NDA‑stage indication)
- Obstructive sleep apnea with obesity
- Metabolic dysfunction‑associated steatohepatitis (MASH)
- Reduction of major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease
- Obesity with knee osteoarthritis
Trial readouts, effect sizes, and head‑to‑head data versus marketed incretin therapies: Not disclosed in the announcement.
Global Partnership – Kailera Therapeutics
- Licensing Structure: In May 2024, Hengrui granted Kailera Therapeutics exclusive rights to develop, manufacture, and commercialize its GLP‑1 innovative drug portfolio — including ribupatide — outside Greater China.
- Global Phase III (Injection): Kailera is currently conducting the KaiNETIC global Phase III clinical trial evaluating ribupatide injection for the treatment of obesity.
- Global Phase III (Oral): Kailera plans to initiate a global Phase III trial of oral ribupatide in obesity in the first half of 2027.
Market Impact & Outlook
- China Diabetes Burden: China has the world’s largest type 2 diabetes population, and NDA acceptance positions ribupatide as a prospective domestic dual GLP‑1/GIP option in a market where incretin competition is intensifying rapidly. Patient‑number figures: Not disclosed.
- Import‑Substitution Angle: As a self‑developed Class 1 asset, ribupatide could offer Chinese payers a domestically sourced alternative to imported dual agonists, with likely advantages in pricing and supply security. Pricing and reimbursement plans: Not disclosed.
- Full‑Spectrum Incretin Play: The breadth of China clinical programs — from weight management and MASH to MACE reduction and obesity‑linked osteoarthritis — mirrors the industry‑wide strategy of extending incretin assets across cardiometabolic disease, and supports multiple future label expansions.
- Dual‑Track Monetization: Hengrui retains Greater China rights while Kailera drives global registration through KaiNETIC and the planned oral Phase III, creating two parallel value paths for a single molecule.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding NMPA review of the ribupatide injection NDA, clinical development across planned indications, Kailera’s global Phase III program, and commercialisation expectations. Actual results may differ materially due to risks including review outcomes and timelines, clinical efficacy and safety findings, competitive dynamics in the incretin class, and partnership execution. NDA acceptance does not guarantee eventual approval.-Fineline Info & Tech